

Actinium Pharmaceuticals, Inc.  
Form 8-K  
February 05, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 5, 2015

**ACTINIUM PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**                      **000-52446**      **88-0378336**  
(State or other jurisdiction   (Commission   (IRS Employer  
of incorporation)              File Number) Identification No.)

**546 Fifth Avenue, 14th Floor**  
**10036**  
**New York, NY**  
(Address of principal executive offices)   (Zip Code)

Registrant's telephone number, including area code: **(646) 459-4201**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

**Item 8.01 Other Events.**

Actinium Pharmaceuticals, Inc. issued a press release on February 5, 2015 announcing a proposed public offering of its common stock and warrants. A copy of the release is attached to this Form 8-K as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

*(d) Exhibits.*

Exhibit 99.1 Press release of Actinium Pharmaceuticals, Inc. dated February 5, 2015

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 5, 2015 **ACTINIUM PHARMACEUTICALS, INC.**

By: */s/ Kaushik J. Dave*

Name: Kaushik J. Dave

Title: President and Chief Executive Officer